Curadigm Nanoprimer Platform

No matter the disease being treated, drug bioavailability — the extent to which a drug enters systemic circulation and accesses the targeted tissues — is critical for therapeutic efficacy.¹ However, in order for a drug to reach the maximally effective concentration at the target tissue, it must overcome a significant biological hurdle: the patient’s own body.

The liver is dedicated to removing compounds from the blood, including many drugs. Due to this process, many promising therapeutic candidates that are administered directly to the blood by IV have poor or suboptimal bioavailability, leading to low or no accumulation in target tissues and potentially high off-target toxicity.² Consequently, while many of these drugs show potential in the lab, many are not viable in the clinic.

To address this challenge, we developed the Curadigm Nanoprimer Platform. The Curadigm Nanoprimer is designed to temporarily increase the bioavailability of subsequently administered therapies while minimizing the risk of off-target effects. This first-in-class concept could unleash the power of innovative therapeutics such as RNA/DNA-based drugs, gene therapies, oncolytic viruses, and nanomedicines by removing a major biological barrier to their success in the clinic. Moreover, solving the liver clearance problem could allow approved drugs to work more efficiently and further improve outcomes for patients.